Spero Therapeutics, Inc. 2HA.F Stock
Spero Therapeutics, Inc. Price Chart
Spero Therapeutics, Inc. 2HA.F Financial and Trading Overview
Spero Therapeutics, Inc. stock price | 1.25 EUR |
Previous Close | 1.49 EUR |
Open | 1.41 EUR |
Bid | 1.42 EUR x 0 |
Ask | 1.48 EUR x 0 |
Day's Range | 1.41 - 1.41 EUR |
52 Week Range | 0.66 - 2.63 EUR |
Volume | 600 EUR |
Avg. Volume | 243 EUR |
Market Cap | 74.02M EUR |
Beta (5Y Monthly) | 0.888028 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0.41 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 38.17 EUR |
2HA.F Valuation Measures
Enterprise Value | -11487427 EUR |
Trailing P/E | N/A |
Forward P/E | -0.4469841 |
PEG Ratio (5 yr expected) | -0.19 |
Price/Sales (ttm) | 1.3833392 |
Price/Book (mrq) | 1.1419302 |
Enterprise Value/Revenue | -0.215 |
Enterprise Value/EBITDA | 0.833 |
Trading Information
Spero Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.888028 |
52-Week Change | 88.43% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.63 EUR |
52 Week Low | 0.66 EUR |
50-Day Moving Average | 1.57 EUR |
200-Day Moving Average | 1.62 EUR |
2HA.F Share Statistics
Avg. Volume (3 month) | 243 EUR |
Avg. Daily Volume (10-Days) | 60 EUR |
Shares Outstanding | 52.57M |
Float | 37.52M |
Short Ratio | N/A |
% Held by Insiders | 18.67% |
% Held by Institutions | 27.37% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -50.18% |
Operating Margin (ttm) | -27.26% |
Gross Margin | 25.99% |
EBITDA Margin | -25.77% |
Management Effectiveness
Return on Assets (ttm) | -7.056% |
Return on Equity (ttm) | -42.18% |
Income Statement
Revenue (ttm) | 53.51M EUR |
Revenue Per Share (ttm) | 1.26 EUR |
Quarterly Revenue Growth (yoy) | 0% |
Gross Profit (ttm) | N/A |
EBITDA | -13794000 EUR |
Net Income Avi to Common (ttm) | -26852000 EUR |
Diluted EPS (ttm) | -0.42 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 96.25M EUR |
Total Cash Per Share (mrq) | 1.83 EUR |
Total Debt (mrq) | 6.38M EUR |
Total Debt/Equity (mrq) | 9.84 EUR |
Current Ratio (mrq) | 4.423 |
Book Value Per Share (mrq) | 1.233 |
Cash Flow Statement
Operating Cash Flow (ttm) | 7.64M EUR |
Levered Free Cash Flow (ttm) | -41517000 EUR |
Profile of Spero Therapeutics, Inc.
Country | Germany |
State | MA |
City | Cambridge |
Address | 675 Massachusetts Avenue |
ZIP | 02139 |
Phone | 857-242-1600 |
Website | https://sperotherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 35 |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Q&A For Spero Therapeutics, Inc. Stock
What is a current 2HA.F stock price?
Spero Therapeutics, Inc. 2HA.F stock price today per share is 1.25 EUR.
How to purchase Spero Therapeutics, Inc. stock?
You can buy 2HA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Spero Therapeutics, Inc.?
The stock symbol or ticker of Spero Therapeutics, Inc. is 2HA.F.
Which industry does the Spero Therapeutics, Inc. company belong to?
The Spero Therapeutics, Inc. industry is Biotechnology.
How many shares does Spero Therapeutics, Inc. have in circulation?
The max supply of Spero Therapeutics, Inc. shares is 54.42M.
What is Spero Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Spero Therapeutics, Inc. PE Ratio is 3.04390260 now.
What was Spero Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Spero Therapeutics, Inc. EPS is 0.41 EUR over the trailing 12 months.
Which sector does the Spero Therapeutics, Inc. company belong to?
The Spero Therapeutics, Inc. sector is Healthcare.